PDCD1 and non-small cell lung carcinoma: The therapeutic success of ICIs in non-small cell lung cancer (NSCLC) has initially been demonstrated by an OS advantage of the anti-PD-1 monoclonal antibody (mAb) nivolumab over docetaxel in palliative second-line among squamous [37] as well as non-squamous [38] NSCLC patients.